SXI Life Sciences
7.550,41
PKT
+25,00
PKT
+0,33
%
Werbung
Analysen zu SXI Life Sciences-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 26.11.19 | Novartis Hold | Deutsche Bank AG | |
| 25.11.19 | Novartis Neutral | Credit Suisse Group | |
| 25.11.19 | Novartis Neutral | UBS AG | |
| 25.11.19 | Roche buy | UBS AG | |
| 25.11.19 | Novartis Conviction Buy | Goldman Sachs Group Inc. | |
| 25.11.19 | Novartis buy | Jefferies & Company Inc. | |
| 25.11.19 | Roche buy | Deutsche Bank AG | |
| 25.11.19 | Roche overweight | JP Morgan Chase & Co. | |
| 18.11.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 14.11.19 | Roche buy | UBS AG | |
| 11.11.19 | Roche buy | UBS AG | |
| 11.11.19 | Roche Neutral | Credit Suisse Group | |
| 11.11.19 | Roche buy | Goldman Sachs Group Inc. | |
| 07.11.19 | Roche buy | UBS AG | |
| 31.10.19 | Novartis Hold | Deutsche Bank AG | |
| 30.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 25.10.19 | Novartis Underweight | Barclays Capital | |
| 24.10.19 | Novartis Neutral | UBS AG | |
| 24.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 24.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 23.10.19 | Novartis Neutral | Credit Suisse Group | |
| 23.10.19 | Novartis Underweight | Barclays Capital | |
| 23.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 22.10.19 | Roche buy | Deutsche Bank AG | |
| 22.10.19 | Novartis buy | Merrill Lynch & Co., Inc. | |
| 22.10.19 | Novartis buy | Jefferies & Company Inc. | |
| 22.10.19 | Novartis Underweight | Morgan Stanley | |
| 22.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 22.10.19 | Novartis Neutral | UBS AG | |
| 22.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 22.10.19 | Novartis Hold | Deutsche Bank AG | |
| 21.10.19 | Roche buy | Goldman Sachs Group Inc. | |
| 21.10.19 | Novartis Underweight | Morgan Stanley | |
| 21.10.19 | Roche overweight | JP Morgan Chase & Co. | |
| 18.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 18.10.19 | Novartis Neutral | UBS AG | |
| 17.10.19 | Roche overweight | Morgan Stanley | |
| 17.10.19 | Roche Neutral | Credit Suisse Group | |
| 17.10.19 | Roche buy | Deutsche Bank AG | |
| 17.10.19 | Roche overweight | Barclays Capital |